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Abstract
Background: The cytogenetic characteristic of Chronic Myeloid Leukemia (CML) is the formation of the
Philadelphia chromosome gene product, BCR-ABL. Given that BCR-ABL is the specific target of Gleevec in CML
treatment, we investigated the regulation of the catalytic component of telomerase, hTERT, by BCR-ABL at multiple
levels in K562 cells.
Methods: Molecular techniques such as over expression, knockdown, real-time PCR, immunoprecipitation, western
blotting, reporter assay, confocal microscopy, telomerase assays and microarray were used to suggest that hTERT
expression and activity is modulated by BCR-ABL at multiple levels.
Results: Our results suggest that BCR-ABL plays an important role in regulating hTERT in K562 (BCR-ABL positive
human leukemia) cells. When Gleevec inhibited the tyrosine kinase activity of BCR-ABL, phosphorylation of hTERT
was downregulated, therefore suggesting a positive correlation between BCR-ABL and hTERT. Gleevec treatment
inhibited hTERT at mRNA level and significantly reduced telomerase activity (TA) in K562 cells, but not in HL60 or
Jurkat cells (BCR-ABL negative cells). We also demonstrated that the transcription factor STAT5a plays a critical role
in hTERT gene regulation in K562 cells. Knockdown of STAT5a, but not STAT5b, resulted in a marked
downregulation of hTERT mRNA level, TA and hTERT protein level in K562 cells. Furthermore, translocation of hTERT
from nucleoli to nucleoplasm was observed in K562 cells induced by Gleevec.
Conclusions: Our data reveal that BCR-ABL can regulate TA at multiple levels, including transcription, post-
translational level, and proper localization. Thus, suppression of cell growth and induction of apoptosis by Gleevec
treatment may be partially due to TA inhibition. Additionally, we have identified STAT5a as critical mediator of the
hTERT gene expression in BCR-ABL positive CML cells, suggesting that targeting STAT5a may be a promising
therapeutic strategy for BCR-ABL positive CML patients.
Background
Chronic myeloid leukemia (CML) was the first human
cancer to be linked to a consistent chromosomal
abnormality [1]. The cytogenetic characteristic of CML
is the formation of the Philadelphia chromosome (Ph),
by the translocation of chromosome 22 and chromo-
some 9. As a result, part of the breakpoint cluster region
(BCR) gene from chromosome 22 fuses with the ABL
gene on chromosome 9. Transcription of this fusion
gene results in constitutively active p210 or p190 BCR-
ABL tyrosine kinase [2], which is detected in 95% of
CML and in 20-30% of adult acute lymphoblastic leuke-
mia (ALL), respectively [3,4]. BCR-ABL has a higher tyr-
osine kinase activity than its cellular counterpart, c-ABL
[5]. The deregulated activity of BCR-ABL leads to
uncontrolled cell proliferation and reduced apoptosis
[6]. BCR-ABL is predominantly localized in the cyto-
plasm where it interacts with various cellular proteins.
These proteins are either phosphorylated by BCR-ABL
or promote phosphorylation of their interaction part-
ners, which in turn triggers the activation of numerous
signaling pathways, including RAS-RAF, MAPK, PI-3-
Kinase, c-JUN and c-MYC pathways [7-10].
As the tyrosine kinase activity of BCR-ABL is essential
for its transforming ability [11], specific targeting of the
BCR-ABL tyrosine kinase provides a promising strategy
for CML therapy. Gleevec (Imatinib mesylate or
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nized CML therapy, is the current gold standard treat-
ment for CML. Gleevec possesses specificity for Abl,
BCR-ABL, c-Kit and the PDGF receptor. It competi-
tively binds to the ATP-binding site of BCR-ABL and
prevents a conformational switch to the oncoprotein’s
active form. This inhibits BCR-ABL activation through
autophosphorylation, and blocks its downstream signal
transduction [12]. About 96% of CML patients exhibited
complete hematologic responses (CHR) and major cyto-
genetic responses (MCR) to Gleevec treatment, and
approximately 55% of ALL patients showed positive
responses to Gleevec treatment [13,14].
Human telomerase is a ribonucleoprotein complex
consisting of two core components, telomerase reverse
transcriptase (human TERT, hTERT) and telomerase
RNA template (human TER, hTER). TERT is a class of
enzyme that creates single-stranded DNA using single-
stranded RNA as a template, whilst TER serves as a
template for addition of telomeric repeats (TTAGGG)
to DNA strands. By using TER, TERT can cap and pro-
tect chromosome ends by adding a six-nucleotide
repeating sequence, 5’-TTAGGG (in all vertebrates, the
sequence differs in other organisms) to the 3’ strand of
chromosomes [15]. The expression of hTERT is the
rate-limiting determinant of human telomerase activity
(TA) and is thought to be a sensitive indicator of telo-
merase function and activity. However, the means by
which TA is regulated remain largely unknown. TA has
been observed in ~85% of all human tumors, suggesting
that the immortality conferred by telomerase plays a key
role in malignant transformation [16]. TA has been
shown to increase in the bone marrow cells of patients
with CML during disease progression [17].
Transfection of the catalytic subunit of telomerase,
hTERT, into cultured human primary cells transformed
with SV40 large T antigen and N-ras oncogene allows
cells to overcome crisis and ultimately achieve malig-
nancy. This suggests that telomerase upregulation may
contribute actively to cellular immortalization and
tumorigenesis, in human cells [18]. Therefore, telomer-
ase can be considered as an attractive target for cancer
diagnosis and anticancer therapy. TA and the expression
of telomerase components are regulated at multiple
levels, including transcription and post-transcription,
accurate assembly, and proper localization [19]. TA can
a l s ob er e g u l a t e da tt h ep o s t - t ranslational level as stu-
dies have shown that protein kinase C (PKC) a and
AKT/protein kinase B (PKB) can upregulate human TA
through phosphorylation of hTERT [20,21].
Several studies have reported that Gleevec can regu-
late TA [22-25]. However, the mechanism by which
Gleevec affects TA in BCR-ABL-expressing cells is
unclear. Contradicting results were obtained from
different studies; some have shown that Gleevec treat-
ment could increase TA and telomere length [26,27],
while a more recent study indicated that Gleevec
reduced TA in K562, BCR-ABL positive cells [25].
Given that BCR-ABL is the specific target of Gleevec,
we surmised that Gleevec affects TA by regulating the
expression and activation of telomerase via BCR-ABL. In
this study, we investigated the effects of Gleevec on TA
in a BCR-ABL positive cell line (K562) and deficient cell
lines (HL60 and Jurkat). Our results indicated that Glee-
vec treatment dramatically inhibits TA and decreases
hTERT expression at the mRNA level in K562, but not in
HL60 and Jurkat cells. Moreover, knocking down of
STAT5a by siRNA resulted in a marked downregulation
of hTERT mRNA level, protein level, and TA in K562
cells. We also found that K562 cells exhibit a significant
increase in hTERT phosphorylation at tyrosine, which
was reduced upon Gleevec treatment in K562 cells, but
absent in HL60 cells. Furthermore, we also observed the
release of hTERT from the nucleoli to the nucleoplasm
of Gleevec-treated K562 cells. These results highlight the
potential role of BCR-ABL in telomerase regulation and
imply that BCR-ABL might regulate telomerase expres-
sion and activity at the transcriptional level via the JAK-
STAT pathway and at the post-translational level
through phosphorylation.
Methods
Cell culture
K562, KU812, HL60 and Jurkat cell lines, obtained from
American Type Culture Collection (ATCC), were cul-
tured in RPMI supplemented with 10% heat-inactivated
FBS, 100 units/ml penicillin, 100 μg/ml streptomycin,
and 2 mM L-glutamine at 37°C in a 5% CO2 incubator.
Approximately 1.5 × 10
5 cells were plated in each well
of a 6-well plate for drug treatment. BCR-ABL-positive
CML patient primary cells (AD155) were obtained with
consent and through an approved protocol from the
Institutional Review Board (IRB) of the National Univer-
sity of Singapore in accordance with the Helsinki
protocol.
Compounds
Gleevec was a gift from Novartis AG. STAT5 inhibitor
(Cat. No. 573108) was obtained from Calbiochem.
STAT5 inhibitor was dissolved in dimethyl sulfoxide
and diluted to a final concentration of 0.1% dimethyl
sulfoxide in all experiments.
Transfection and infection
Recombinant lentivirus (GFP-hTERT IRES hygro) was
produced by co-transfecting 4 μg of pMD.G plasmid, 8
μgo fp C M V D R 8 . 9 1a n d1 2μg of lentivector into 293T
cells (ATCC) using Lipofectamine 2000 (Invitrogen).
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48 h post transfection and filtered through 0.45-μmf i l -
ters. K562, HL60 and Jurkat cells were incubated with
medium containing virus supplemented with 8 μg/ml
polybrene for 24 h. Cells were selected with hygromycin
for 3-5 days prior to drug treatment.
Gel-based TRAP assay
Measurement of TA was performed by the PCR-based
TRAP (Telomeric repeat amplification protocol) assay,
using the TRAPEZE telomerase detection kit (Millipore),
according to the manufacturer’si n s t r u c t i o n s .C e l l sw e r e
harvested using ice-cold CHAPS (3-[(3-cholamidopropyl)
dimethylammonio]-1-propane sulphonate) lysis buffer and
incubated for 30 min on ice. Cells were clarified by centri-
fugation at 12000 g for 20 min at 4°C. Telomerase extracts
were assayed for TA by TRAP analysis. Each reaction was
performed in 50 μL reaction mixture containing 10X
TRAP reaction buffer, 50X dNTP mix,
32P-TS primer,
TRAP primer mix and Taq polymerase (5 units/μL). 2-
step PCR was performed at 30°C for 30 min and was then
subjected to PCR amplification for 27 cycles at 94°C for 30
sec, 59°C for 30 sec each. PCR products were separated by
electrophoresis on a 10% urea gel (National Diagnostics)
in a T-REX™ Aluminum Backed Sequencer Model S3S
(Owl). Gel was transferred using filter papers into a cas-
sette, incubated for 1 week with phosphoimager and was
then scanned using Typhoon Trio Imager (Amersham
Biosciences). Quantifications were performed using Ima-
geQuant TL (Amersham Biosciences) and TA was nor-
malized with the 36 bp internal PCR control.
Quantitative telomerase assay
TA was quantified using telomeric repeat amplification
protocol (TRAP) as described by the TeloExpress Quan-
titative Telomerase Detection Kit (XpressBio). Cells
were lysed with 50 μlo fT e l o E x p r e s sL y s i sb u f f e ra n d
approximately 1 μg of DNA was used for real-time PCR.
TA in each sample was calculated based on the compar-
ison with the Ct values of a standard curve generated
from 10-fold dilutions of telomerase control (TC) oligo
with known copy numbers of the telomeric repeats.
Telomere length assay
DNA was extracted from the cells using DNeasy Blood
& Tissue Kit (Qiagen). Telomere length analysis was
carried out using a non-radioactive TeloTAGGG Telo-
mere Length Assay (Roche) as described by the manu-
facturer. Approximately 1 μgo fD N Ao fe a c hs a m p l e
was digested with Hinf I/Rsa I enzyme mix and sepa-
rated by gel electrophoresis. DNA fragments were trans-
ferred to nylon membrane (Amersham, GE) by southern
transfer and hybridized to digoxigenin (DIG-labeled
probe), specific for telomeric repeats. A DIG-specific
antibody conjugated to alkaline phosphatase was then
used to incubate the membrane and the probe was then
visualized by chemiluminescence detection and subse-
quent exposure to X-ray film (Amsersham, GE). Mean
telomeric repeat binding factor (TRF) lengths were
determined by comparison to the molecular weight
standard provided.
STELA
XpYp single telomere length assay (STELA) was per-
formed using the methods described by Baird et al. [28].
Total number of telomere bands from the lanes for each
sample were pooled and calculated. Telomere shorten-
ing was quantified by determining the percentage of tel-
omere bands less than 1.0 kb to the total number of
bands in the sample.
RT-PCR
One step RT-PCR was performed using the Qiagen One
Step RT-PCR kit following manufacturer’s protocol. The
following primers were used: 5’-CGTGGTTTCT
GTGTGGTGTC-3’ (human TERT forward primer) and
5’-CCTTGTCGCCTGAGGAGTAG-3’ (human TERT
reverse primer), 5’-GCCTTCCACCGTTCATTCTA-3’
(human TER forward primer) and 5’-GCTGACA-
GAGCCCAACTCTT-3’ (human TER reverse primer),
5’-GAGAGACCCTCACTGCTG-3’ (GAPDH forward
primer) and 5’-GATGGTACATGACAAGGTGC-3’
(GAPDH reverse primer). PCR products were run on
2% agarose gel and viewed under UV Gel Doc (BioRad).
Quantifications were performed using Quantity One
(BioRad).
Real-time PCR
Reverse transcription was performed using the Promega
RT-PCR kit and oligo dT primer as per manufacturer’s
protocol (Promega). Real-time PCR was performed
using Brilliant SYBR Green qPCR Master Mix on the
Rotorgene real-time system (Qiagen). The following pri-
mers were used for real-time PCR: 5’-GGAGCT
GGTGGTTGACTTTC-3’ and 5’-CTCCGATTCAGTCC
CTTCTG-3’ (human BCL2), 5’-ATACCATGATAGCG
CCCTTG-3’ and 5’-AATCACAGCGAACCTCTGCT-3’
(human PI3KCG), 5’-CCCTCGGTGTCCTACTTCAA-3’
and 5’-AGGAAGCGGTCCAGGTAGTT-3’ (human
CCND1), 5’-TGCCAAGAGTCTAGCCCAGT-3’ and 5’-
TCCACTGTTCATAGGGCACA-3’ (human PFKFB4),
5’-ATGCGACAGTTCGTGGCTCA-3’ and 5’-ATCCCC
TGGCACTGGACGTA-3’ (human TERT), 5’-GTGGAC
CTGACCTGCCGTCT-3’ and 5’-GGAGGAGTGGG
TGTCGCTGT-3’ (human GAPDH). Data were analyzed
using the ΔΔCT method.
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Cells were harvested for protein at different time points.
Briefly, cells were resuspended in 50 mmol/L Tris-HCl
(pH 7.4), 250 mmol/L NaCl, 5 mmol/L EDTA, and 0.1%
NP40 containing protease and phosphatase inhibitors.
Lysates were cleared by centrifugation at 14,000 rpm for
10 min, and samples were run on SDS-PAGE gels. Wes-
tern blotting was performed with the following antibo-
dies: rabbit anti-BCR-ABL (Cell Signaling), rabbit anti-
hTERT (Epitomics), rabbit anti-pSTAT5 (Tyr694)
C11C5 (Cell Signaling), mouse anti-pTyr (Millipore) and
phospho-abl (Tyr412) (Millipore). Mouse anti-a-tubulin
(Sigma) or Horseradish peroxidase (HRP)-conjugated
mouse anti-b-actin (Abcam) or mouse anti-GAPDH
(Cell Signaling) were used as loading controls. Immu-
nostaining was detected using ECL Plus Detection
Reagent (GE Healthcare).
Immunoprecipitation
After Gleevec treatment, K562 and HL60 cells were
rinsed in cold PBS and lysed in a RIPA buffer. Cell
lysate was kept on ice for 10 min and centrifuged for 10
min at 12,000 g, 4°C. 2 μlo fa n t i - h T E R Ta n t i b o d y
(Abcam) was added to 200 μl of cell lysate and incu-
bated overnight at 4°C. 20 μl of protein A agarose beads
(50% bead slurry) was added for 3 h at 4°C. Samples
were centrifuged for 30 sec at 4°C. Pellets were washed
five times with lysis buffer. Laemmli buffer was added
and samples were boiled at 100°C for 5 min. Samples
were centrifuged for 1 min at 14,000 g, and supernatants
analysed by Western blotting. The tyrosine phosphoryla-
tion level of hTERT was examined by anti-phosphotyro-
sine antibody (Millipore).
siRNA transfection
siRNA oligos for knockdown of endogenous human
STAT5a and STAT5b proteins and Negative Control
(Scramble) siRNA were purchased from Ambion. Trans-
fections were performed by Amaxa nucleofection
(Lonza), by using program T-016 (K562 cells) or T-019
(HL60 cells) as per manufacturers’ instructions.
Luciferase reporter assay
HeLa cells were seeded in 24-well plates and co-trans-
fected with hTERT promoter (-3915 ~ +40) luciferase
construct (pGL3- hTERT), pMX-STAT5a, pMX-
STAT5b, or pMX (vector control) using Lipofectamine
2000 (Invitrogen). Forty-eight hours following transfec-
tion, cells were harvested and subjected to the luciferase
assay using the dual-luciferase reporter assay kit (Pro-
mega). The pRL-SV40 driving Renilla reniformis lucifer-
ase was included in each transfection as a control to
normalize the transcriptional activity of hTERT
promoter fragments. Standard deviations were derived
from three independent experiments.
Confocal microscopy
K562, HL60 and Jurkat cells were infected with GFP-
hTERT IRES hygro expressing virus. Cells were cytos-
pun according to Shandon Cytospin Program and then
fixed with 2% paraformaldehyde in PBS, and permeabi-
lized with 0.2% Triton X-100 in PBS. Immunostaining
was performed using primary antibodies against fibril-
larin (Cell Signaling) followed by appropriate secondary
antibody conjugated with Alexa Fluor 568 antibody
(Invitrogen). DNA was visualized with 0.2 μg/mL of
4’,6-diamidino-2-phenylindole (DAPI) and all images
were analyzed using Olympus Fluoview FV100 micro-
scope with 60× objective.
Illumina microarray analysis
RNA was isolated from K562 and HL60 cells, non-trea-
ted or treated with 1 μM of Gleevec for 8 h, using the
RNeasy kit with on-column DNase digestion (Qiagen).
Quality of RNA from each sample was assessed using
the RNAnalyzer (Biorad), all with an RNA integrity
number > 7, and 500 ng of RNA was converted to
cRNA using the Illumina TotalPrep RNA Amplification
kit (Ambion). Labeled cRNA was prepared and hybri-
dized overnight for 18 h to Illumina HumanRef-8_V2
array containing 18,126 human genes, which was then
washed and stained with streptavidin-Cy3 (Amersham-
Pharmacia Biotech) according to the manufacturer’s
guidelines (Illumina) and arrays were scanned on a Bea-
dArray Reader (Illumina). Using the Partek software,
statistical significance of global gene expression levels
were analyzed by Analysis of Variance (ANOVA) at
false discovery rate (FDR) < 0.05 and were defined as
genes with two-fold up or downregulation. Microarray
data is available in MAIME-compliant form at NCBI
Gene Expression Omnibus (http://www.ncbi.nlm.nih.
gov/geo) under accession number GSE26821.
Results
Gleevec specifically inhibits TA in BCR-ABL positive cells
Since telomerase plays a critical role in tumorigenesis,
the effects of different drugs on TA are of potential
importance [29]. In this study, we found that Gleevec
significantly decreased K562 cells viability and prolifera-
tion within 48 h (Additional file 1: Figure S1). This
result is in agreement with previous studies, which
demonstrated that the inhibitory effect of Gleevec on
leukemia cells is at least partially due to its inhibitory
effect on telomerase activity [23,25,30].
In order to attest the mechanism of Gleevec on TA
and its regulation, TA of BCR-ABL positive (K562) and
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Page 4 of 16Figure 1 Gleevec reduces TA in K562 cells.( a) The Gel-based TRAP assay was performed with
32P-ATP labeled TS primer using the 2-step PCR
conditions: 94°C/30 sec and 59°C/30 sec for 27 cycles. The amount of extract (expressed as cell number) present in telomerase-positive samples
(293T, K562, HL60 and Jurkat) and negative controls (IMR90 and samples with RNase) is shown above each lane. K562, HL60 and Jurkat cells
were subjected to 1 μM Gleevec treatment for 16 h. (b) Normalized relative TA from Gel-based TRAP assay was determined using ImageQuant
TL in non-treated and 1 μM Gleevec treated K562, HL60 and Jurkat cells for 16 h. (c) Quantitative telomerase assay showing relative TA in K562
cells. Error bars represent standard deviation from three experiments. (d) Telomere length assay of K562, HL60 and Jurkat cells under Gleevec
treatment. (e) Percentage of telomeres less than 1.0 kb as determined by STELA after 1, or 3 weeks with 0.05 μM Gleevec
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Page 5 of 16deficient (HL60 and Jurkat) cells were assessed by gel-
based Telomeric Repeat Amplification Protocol (TRAP)
assay following 16 h of Gleevec treatment. TRAP results
showed that K562 cells have a significantly higher TA
(~50% higher) than HL60 or Jurkat cells (Figure 1a and
1b). However, upon 1 μM Gleevec treatment, we
observed that TA in K562 cells was reduced by ~70%.
Nevertheless, this effect of Gleevec was not evident in
BCR-ABL deficient cells, i.e., HL60 and Jurkat cells (Fig-
ure 1a and 1b). On the other hand, TRAP results also
indicated that Gleevec treatment had no effect on telo-
merase processivity in both BCR-ABL positive and defi-
cient cells (Figure 1a). To further confirm the effect of
Gleevec on TA in K562 cells, Quantitative Telomerase
Assay was also performed. Treatment of 1 μM Gleevec
for 2 h resulted in a significant reduction of TA in K562
cells, which was consistent with the gel-based TRAP
assay result (Figure 1c). To avoid cell specific effects,
another BCR-ABL positive cell line, KU812 and BCR-
ABL positive CML patient cells, AD155, were used to
determine Gleevec effect on TA. Our results also
showed a significant decrease in TA in KU812 and
AD155 cells under Gleevec treatment (Additional file 1:
Figure S2). These results indicate that Gleevec specifi-
cally inhibits TA in BCR-ABL positive cells, i.e., K562,
KU812, and AD155 cells.
To investigate the effect of Gleevec on telomere
length, K562, HL60, and Jurkat cells were treated with
Gleevec and telomere lengths were quantified using
Southern Blotting. Telomere signals appeared as a broad
smear of densities. Mean telomere length of K562,
HL60, and Jurkat cells were 3.4 kb, 2.9 kb and 3.8 kb,
respectively (Figure 1d) and the result showed that there
was no significant change in telomere length upon Glee-
vec treatment. This could presumably be due to the
short treatment period of cells with Gleevec, preferred
within 24 h.
We next questioned if Gleevec would induce a longer
term effect on telomere length of K562 cells. We used
subapoptotic concentrations of Gleevec [31] to treat the
cells for a longer period. K562 cells were cultured for
up to 3 weeks with 0.05 μM Gleevec. Cells were col-
lected at week 1 and week 3 and then subjected to telo-
mere length determination using the single telomere
length assay (STELA) [28]. Telomere shortening was
quantified by determining the percentage of telomere
bands less than 1.0 kb to the total number of bands in
the sample. As shown in Figure 1e, Gleevec did not
induce visible telomere length shortening after 1 week
treatment. After 3 weeks treatment, however, K562 cells
displayed a significantly increased proportion of shor-
tened telomeres (< 1.0 kb), suggesting that Gleevec has
a long-term effect on telomere length via inhibiting TA.
Gleevec specifically downregulates hTERT mRNA level in
BCR-ABL positive cells
To elucidate the mechanism of Gleevec’si n h i b i t o r y
effect on TA in BCR-ABL positive cells, RT-PCR was
performed to quantify hTERT and hTER mRNA levels
in K562, HL60, and Jurkat cells. The basal level of
hTERT i st h es a m et h r o u g h o u tt h et h r e ec e l ll i n e s ,
although the level of hTER is higher in BCR-ABL posi-
tive K562 cells as compared to BCR-ABL deficient HL60
and Jurkat cells. Gleevec treatment for 16-hour signifi-
cantly reduced the hTERT mRNA level in K562 cells
compared to the non-treated control, but the same
Gleevec treatment had no effect on hTERT mRNA level
in BCR-ABL deficient HL60 or Jurkat cells (Figure 2a).
Same samples were subjected to real-time PCR for vali-
dation of the result shown in RT-PCR. Real-time PCR
result also showed reduced hTERT mRNA level, by
~60%, upon 16-hour treatment in K562 cells, which
showed consistency with the RT-PCR result (Additional
file 1: Figure S3). In addition, hTERT mRNA level was
gradually reduced with increasing Gleevec incubation
time, suggesting a direct positive correlation between
Gleevec targeted pathway and hTERT expression (Figure
2b). However, hTER mRNA levels remained unchanged
in both the BCR-ABL positive and deficient cells treated
with Gleevec (Figure 2a). These data suggested that
Gleevec inhibited TA rapidly by specifically reducing
hTERT mRNA level in BCR-ABL positive K562 cells.
Similar result was also shown in KU812 cells by using
real-time PCR (Additional file 1: Figure S4).
We next conducted a microarray analysis to examine
the gene expression changes between control and 8 h
Gleevec-treated cells. We first compared K562 non-trea-
ted cells with HL60 non-treated cells and then further
analysed the comparison between K562 Gleevec-treated
cells with K562 control cells. From our microarray ana-
lysis, we noted distinct profiles of gene expression
changes in both sets of comparisons. In K562 control
cells versus HL60 control cells, a total of 855 and 2182
genes were significantly upregulated and downregulated,
respectively (with a p value < 0.05 and fold change > or
< 2). When comparing K562 Gleevec-treated cells versus
K562 control cells, 1114 genes were significantly upre-
gulated and 113 observed to be significantly downregu-
lated (with a p value < 0.05 and fold change > or < 2)
(Additional file 1: Figure S5). Overlapping genes are
listed in Additional file 1 (Table S1). We next sought to
identify the gene sets that were enriched in K562 Glee-
vec-treated group versus K562 control group. This was
achieved through the comparison of our array data
against known curated gene sets available from Molecu-
lar Signatures Database (MSigDB). In agreement to our
Western results, our gene set analysis revealed that a
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treated set were grouped under the JAK/STAT path-
way (Table 1A). Three genes were selected from
Table 1B and further validated by real-time PCR
(Additional file 1: Figure S6-8, Table S2). In particu-
lar, we noted a downregulation of PIK3CG (also
known as PI3K), a gene coding for the catalytic com-
ponent of phosphoinositide-3-kinase (PI3K), a non-
receptor tyrosine kinase (Table 1B). A significant dif-
ference of almost 3 folds downregulation was
observed when K562 cells were treated with Gleevec
as compared to K562 control cells (Additional file 1:
Figure S7). Though we did not observe any significant
downregulation of hTERT mRNA in microarray ana-
lysis, real-time PCR results showed considerable
hTERT mRNA downregulation in Gleevec-treated
K562 cells (Additional file 1: Figure S9, Table S2).
The discordance of hTERT gene expression result
may be explained by the decreased sensitivity of the
microarray gene expression change compared to real-
time PCR. But, we noted many upregulated genes that
were enriched in gene sets involved in telomere main-
tenance, telomere extension and telomere ends packa-
ging (Additional file 1: Table S3A & B).
Next, we determined whether Gleevec could inhibit
hTERT expression at the protein level in K562 cells
treated with 1 μM of Gleevec at different time points.
Surprisingly, there was no significant alteration in the
protein expression level of hTERT upon 16 h of Glee-
v e ct r e a t m e n t( F i g u r e2 c ) .T h i sc o u l db ed u et oas h o r t
half-life of hTERT mRNA (~2 h) [32] compared to the
l o n gh a l f - l i f eo fh T E R Tp r o t e i n( ~ 2 4h )i nK 5 6 2c e l l s
(Additional file 1: Figure S10) [33], resulting in an
indirect correlation between the protein level and the
transcriptional level. We have extended the Gleevec
treatment beyond 24 h, and we did not observe any
marked change in hTERT protein expression level at
24 and 36 h. There is a slight decrease in hTERT pro-
tein level at 48 h. This suggested that Gleevec has no
significant effect on reducing the rate of hTERT degra-
dation in short-term treatment (Additional file 1: Fig-
ure S11). Besides, we observed and confirmed in
Figure 2c that Gleevec reduces the tyrosine kinase
activity of BCR-ABL by abolishing the phosphorylation
of BCR-ABL and therefore eliminates the phosphoryla-
tion of STAT5 (Signal Transducer and Activator of
Transcription 5). STAT5 is activated by BCR-ABL and
is implicated in the pathogenesis of CML. Since
STAT5 is a well-known transcriptional activator and
has been proven to function as a transcriptional regu-
lator of hTERT [34], these evidences led us to hypothe-
size that BCR-ABL plays a critical role in regulation of
hTERT expression through the STAT5 signaling
pathway.
Figure 2 Gleevec reduces hTERT mRNA level in K562 cells.( a)1
μM Gleevec treatment for 16 h inhibits hTERT mRNA level in K562 but
not in HL60 and Jurkat cells. Upper Panel: RT-PCR image; Lower Panel:
Quantitation of the RT-PCR image. (b) hTERT mRNA level in K562 cells
was gradually reduced with increased incubation time upon 1 μM
Gleevec treatment. Upper Panel: RT-PCR image; Lower Panel:
Quantitation of the RT-PCR image. (c) Endogenous proteins expression
level of K562 cells under 1 μM Gleevec treatment for 2, 8 and 16 h
Chai et al. BMC Cancer 2011, 11:512
http://www.biomedcentral.com/1471-2407/11/512
Page 7 of 16STAT5a plays a critical role in hTERT gene expression in
K562 cells
STAT5 inhibitor was used to examine the specific role
of STAT5 in the expression of hTERT mRNA in BCR-
ABL positive or negative cells. K562 and HL60 cells
were treated with either STAT5 inhibitor or vehicle.
After 48 h, cells were subjected to determination of
hTERT mRNA and TA. Real-time PCR revealed that
STAT5 inhibitor treatment caused a significant decrease
in expression of hTERT in K562 cells, but not in HL60
cells. Moreover, we found that STAT5 inhibitor specifi-
cally inhibited TA in K562 cells (Figure 3a).
In order to investigate whether STAT5 could activate
the hTERT gene promoter, we examined hTERT promo-
ter activation by STAT5 using a luciferase reporter assay.
A 3.9 kb fragment of the human wild-type hTERT pro-
moter was fused to the pGL3-basic luciferase reporter
vector [35]. HeLa cells were transiently co-transfected
with the hTERT full-length promoter construct (pGL3-
hTERT) and pMX-STAT5a or pMX-STAT5b, while
empty vector was used as a control [36]. Activation of
the hTERT promoter was measured by luciferase activity.
HeLa cells transfected with STAT5a showed a 2.7-fold
increase in luciferase activity compared to control cells,
while the induction of luciferase activity in the presence
of exogenous STAT5b was not statistically significant
(Figure 3b). This indicated that the hTERT promoter was
significantly activated by STAT5a, but not STAT5b.
Next, we verified the importance of STAT5 in hTERT
gene expression by siRNA assay. K562 cells were trans-
fected with STAT5a siRNA, STAT5b siRNA or scramble
siRNA, respectively. The ability and specificity of
STAT5a and STAT5b siRNAs were first examined by
immunoblotting. Figure 3c showed the scramble siRNA
did not affect the expression of STAT5a or STAT5b. As
shown in Figure 3c, when STAT5a protein level was
70% reduced, hTERT mRNA levels, together with TA,
were clearly downregulated after 72 h of post-transfec-
tion with STAT5a siRNA, whereas the STAT5b siRNA,
which reduced STAT5b protein level significantly by
80%, did not affect hTERT mRNA levels as well as TA
(Figure 3d). In agreement with these results, we also
found knockdown of STAT5a, but not STAT5b, resulted
in marked reduction in hTERT protein level (Figure 3c).
When same experiments were carried out in HL60,
BCR-ABL negative cells, STAT5a silencing showed no
effect on hTERT mRNA expression and TA (Additional
file 1: Figure S12).
Taken together, these data strongly suggested that
activated STAT5a, but not STAT5b, plays a critical role
in telomerase regulation in K562, BCR-ABL positive
cells. These findings also indicated that BCR-ABL could
Table 1 Comparison between K562 Gleevec-treated group versus K562 control group.
A. K562 Gleevec-treated group versus K562 control group
Function Enrichment Score Enrichment p-value # genes in list, in
group
KEGG JAK STAT
SIGNALING PATHWAY
12.616000 0.000003 8
ST STAT3 PATHWAY 6.219490 0.001990 2
B. JAK-STAT Signaling Pathway
Gene Symbol Definition p-value(K562 Treated vs.
K562 Control)
Fold-Change
(K562 Treated vs.
K562 Control)
BCL2L1 Homo sapiens BCL2-like 1 (BCL2L1), nuclear gene encoding
mitochondrial protein, transcript variant 1, mRNA.
0.000076 -2.336810
CISH Homo sapiens cytokine inducible SH2-containing protein (CISH),
mRNA.
0.000754 -2.926860
CCND1 Homo sapiens cyclin D1 (CCND1), mRNA. 0.000964 -9.480380
SPRED1 Homo sapiens sprouty-related, EVH1 domain containing 1 (SPRED1),
mRNA.
0.001425 -3.138930
SOCS1 Homo sapiens suppressor of cytokine signaling 1 (SOCS1), mRNA. 0.003518 -2.455500
IL6 Homo sapiens interleukin 6 (interferon, beta 2) (IL6), mRNA. 0.004541 -2.036640
PIK3CG Homo sapiens phosphoinositide-3-kinase, catalytic, gamma
polypeptide (PIK3CG), mRNA.
0.005740 -2.292180
PIM1 Homo sapiens pim-1 oncogene (PIM1), mRNA. 0.006760 -2.343000
(a) Gene set analysis showing enrichment of gene sets under JAK/STAT pathway. These gene sets showed the number of genes that are downregulated in this
pathway in K562 Gleevec-treated cells. (b) List of downregulated genes related to JAK/STAT pathway in K562 Gleevec-treated cells
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Page 8 of 16Figure 3 STAT5a plays important role in hTERT mRNA expression.( a) HL60 and K562 cells were treated with vehicle (DMSO) or STAT5
inhibitor (50 μM) for 48 h, after that cells were harvested. Expression of hTERT was measured using real-time PCR and normalized to the
expression of GAPDH. TA was determined by quantitative telomerase assay. (b) K562 cells were co-transfected with empty vector (pGL3) or with
a luciferase construct containing the hTERT promoter (pGL3-hTERT) together with empty expression vector (pMX) or STAT5a or STAT5b
expression construct (pMX-STAT5a or pMX-STAT5b). Luciferase activity was determined 48 h after transfection and was normalized to empty
expression vector. Each luciferase assay was repeated 3 times. (c) K562 cells were transfected with Scramble siRNA (non-targeting siRNA), STAT5a
siRNA, STAT5b siRNA, or non-transfected (Mock). Cells were lysed after 72 h post-transfection. Total amount of STAT5a, STAT5b and hTERT were
shown by Western blotting, and quantitated by normalization over the expression of b-Actin using ImageJ. (d) After 72 h post-transfection, K562
cells were collected and hTERT mRNA expression level and TA were measured by real-time PCR and quantitative telomerase assay, respectively
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level through the JAK-STAT pathway.
Gleevec regulates human TA and hTERT phosphorylation
through inhibition of BCR-ABL kinase activity
Some studies showed that protein kinase C (PKC) a and
AKT/protein kinase B (PKB) can upregulate human TA
through phosphorylation of hTERT [20,21]. Given that
BCR-ABL functions as a tyrosine kinase, we questioned
whether BCR-ABL could also directly enhance TA
through phosphorylation of hTERT. To address this
question, we analyzed the phosphorylation level of
hTERT using anti-phosphotyrosine antibody in both
BCR-ABL positive (K562) and BCR-ABL deficient
(HL60) cells. Compared to HL60 cells, the tyrosine
phosphorylation level in K562 cells was markedly
increased (Figure 4a), suggesting that the increase in tyr-
osine phosphorylation is due to BCR-ABL tyrosine
kinase activity, which was confirmed by the expression
of BCR-ABL shown only in K562 cells. Interestingly, we
found a significant increase in tyrosine-phosphorylation
at the corresponding molecular weight of hTERT (122
kDa) in K562 cells compared to HL60 cells. This result
led us to consider that hTERT could be phosphorylated
at tyrosine residues by BCR-ABL in K562 cells. To eval-
uate this possibility, hTERT was immunoprecipitated by
anti-hTERT antibody from both K562 and HL60 cell
lysates and resolved by SDS-PAGE followed by immu-
noblotting with anti-phosphorylation antibody. We
found that hTERT tyrosine phosphorylation was signifi-
cantly elevated in K562 cells compared to HL60 cells
(Figure 4b). As the expression level of hTERT was simi-
lar in both cells, the result suggested that hTERT could
be presumably phosphorylated by BCR-ABL.
To further determine whether BCR-ABL phosphory-
lates hTERT, we treated K562 cells with 1 μM Gleevec,
and evaluated the phosphorylation status of hTERT. If
h T E R Ti sas u b s t r a t eo fB C R - A B L ,w ew o u l de x p e c t
Gleevec treatment to decrease the phosphorylation level
of hTERT and its activity. As shown in Figure 4c, Glee-
vec treatment resulted in almost complete inhibition of
hTERT phosphorylation at tyrosine residues compared
to control cells. To demonstrate that the decrease in tyr-
osine phosphorylation of hTERT was not due to
reduced hTERT expression level, western blot was per-
f o r m e da n dw ed i dn o to b s e r v ead i f f e r e n c ei nh T E R T
expression level in Gleevec-treated K562 cells compared
to control cells (Figure 4c). We also examined the inter-
action between BCR-ABL and hTERT using immuno-
precipitation assay. Surprisingly, there was no evidence
of direct interaction between BCR-ABL and hTERT
(data not shown).Overall, these results suggested that
BCR-ABL can regulate TA by post-translational modifi-
cation of hTERT through tyrosine phosphorylation.
Gleevec inhibits hTERT nucleoli translocation in K562
BCR-ABL positive cells
It is known that phosphorylation of hTERT is important
for its nuclear translocation [37]. We subsequently
examined the localization of hTERT in K562, HL60, and
Jurkat with and without Gleevec treatment. Confocal
microscopy was carried out to study Gleevec’s effect on
hTERT cellular distribution in K562, HL60, and Jurkat
cells. These three cell lines were infected with GFP-
hTERT as the endogenous level of hTERT could not
easily be detected in these cells by immunofluoresence
microscopy. They were then either left untreated (Figure
5a, c and 5e) or treated with Gleevec for 16 h (Figure
5b, d and 5f). Images were merged for two colors: GFP-
hTERT (green) and fibrillarin (red), the latter was used
as a marker for nucleoli while the nucleus was stained
with DAPI. A concentrated localization of hTERT was
observed in nucleoli of non-treated K562 cells (Figure
5a and 5g), but not in HL60 and Jurkat cells (Figure 5c
and 5e). Gleevec treatment induced dissociation of
hTERT from nucleoli of K562 cells to nucleoplasm (Fig-
ure 5b). This finding indicated that hTERT could partly
have translocated into the nucleoplasm or was pre-
vented from binding to nucleoli upon Gleevec treat-
ment. In contrast, HL60 and Jurkat cells showed that
hTERT was mainly dispersed in the nucleoplasm but
not concentrated in nucleoli (Figure 5c-f).
Discussion
Previous studies have suggested that treatment of Glee-
vec could inhibit TA through suppressing hTERT
mRNA level and hTERT phosphorylation level; the lat-
ter is regulated by serine/threonine protein kinase AKT
[20,21]. However, the mechanism by which Gleevec
inhibits TA in BCR-ABL positive cells remains largely
unknown. Given the clinical significance of BCR-ABL in
leukemia treatment, we sought to investigate the roles
of BCR-ABL in CML and its relationship with telomer-
ase regulation, in order to facilitate in the development
of better anti-CML drugs. We found that Gleevec inhi-
bits TA through BCR-ABL by two separate mechanisms:
(1) by reducing the hTERT mRNA level via suppressing
BCR-ABL mediated STAT5 signaling pathway; (2) by
inhibiting phosphorylation of hTERT that can reduce
TA and induce hTERT cellular translocation.
Our RT-PCR results showed that hTERT mRNA is
dramatically reduced in the presence of Gleevec. The
reduction of expression is only found in hTERT but not
in hTER of telomerase in K562 cells. This implies that
Gleevec only affects the catalytic component of telomer-
ase. Moreover, Gleevec treatment of K562 cells resulted
in a significant decrease in TA but has no effect on the
processivity of the telomerase. Our results are consistent
with previous findings that TA is inhibited in BCR-
Chai et al. BMC Cancer 2011, 11:512
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Page 10 of 16Figure 4 Post-translational regulation and phosphorylation of BCR-ABL on hTERT.( a) Global protein tyrosine-phosphorylation level and
BCR-ABL expression in K562 and HL60 cells. (b) Phosphorylation of hTERT at tyrosine residues was higher in K562 cells compared to HL60 cells.
(c) Gleevec treatment led to a loss of phosphorylation of hTERT at tyrosine residues
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Page 11 of 16ABL-positive cells by Gleevec and this inhibition is spe-
cific to telomerase [25].
It is known that telomerase inhibition can reduce telo-
mere length to a critical threshold resulting in senes-
cence and/or apoptosis. We examined Gleevec’s effect
on telomere length in K562 cells and observed telomere
shortening following 3 weeks of exposure to sub-apop-
totic concentrations of Gleevec, while short-term
Gleevec treatment showed no significant effect on telo-
mere length. The efficacy of long-term telomerase inhi-
bition suggests that Gleevec may inhibit K562 cell
growth and proliferation by modulating telomere length.
From the microarray analysis, we found that PI3K was
downregulated in the JAK/STAT signaling pathway in
Gleevec-treated K562 cells as compared to the K562
control group. Previous study has shown that BCR-ABL
Figure 5 Gleevec treatment of K562 (BCR-ABL positive) cells induces translocation of telomerase out of the nucleoli. K562, HL60 and
Jurkat cells were infected with GFP-hTERT. Representative immunofluorescence images of (a) K562 GFP-hTERT non-treated cells; (b) K562 GFP-
hTERT treated cells with 1 μM Gleevec for 16 h; (c) HL60 GFP-hTERT non-treated cells; (d) HL60 GFP-hTERT treated cells with 1 μM Gleevec for 16
h; (e) Jurkat GFP-hTERT non-treated cells; and (f) Jurkat GFP-hTERT treated cells with 1 μM Gleevec for 16 h. (g) Representative enlarged image of
GFP-hTERT infected K562 cells displaying colocalization of GFP-hTERT with fibrillarin. Blue: DAPI; Green: GFP-hTERT; Red: Fibrillarin. All images
were taken using Olympus Fluoview FV1000. Bar, 30 μm
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phosphatidylinositol-3,4,5-trisphosphate (PIP3), which is
a second messenger that activates and recruits down-
stream effector proteins such as the serine/threonine
kinase AKT [38]. Thus, this suggests that the downregu-
lation of PI3K is due to the inhibition of BCR-ABL tyro-
sine kinase activity via the JAK/STAT pathway upon
Gleevec treatment in K562 cells, which may ultimately
reduce TA in these cells.
STAT family proteins function as downstream effec-
tors of a variety of cytokines and growth factors. STAT
factors transmit signals to t h en u c l e u sw h e r et h e yb i n d
to specific DNA promoter sequences and thereby regu-
late gene expression [39]. Numerous studies have
demonstrated that constitutively activated STAT factors,
particularly STAT3 and STAT5, have been found in a
wide variety of human tumors, including blood malig-
nancies (leukemias, lymphomas) [40,41]. Constitutively
activated STAT factors are linked to persistent activity
of tyrosine kinases, such as BCR-ABL, Src, and many
others.
In this study, we observed and confirmed that STAT5
was phosphorylated only in BCR-ABL positive K562
cells and 2-hour Gleevec treatment completely abolished
the phosphorylation of STAT5, which is in agreement
with previous findings describing that STAT5 pathway
is constitutively activated by p210 BCR-ABL and p190
BCR-ABL in leukemic cells [42,43]. BCR-ABL directly
phosphorylates STAT5 at tyrosine residues and pro-
motes dimerization of phosphorylated STAT5 followed
by nuclear translocation of the dimers that then pro-
mote activation of downstream target genes, which are
important to induce or maintain cancer cell growth and
survival. A previous report showed that inhibition of
BCR-ABL, as well as STAT5, by a selective inhibitor,
suppressed cell proliferation and induced apoptosis in
the BCR-ABL/STAT5 double positive K562 CML cell
line, while this inhibitor had no effect on either a BCR-
ABL-negative/STAT5-positive or a BCR-ABL/STAT5
double-negative myeloid cell line, suggesting that the
STAT5 signaling pathway leading to growth and survival
is BCR-ABL-dependent [44]. Some studies demonstrated
that STAT5 activation is absolutely essential for leuke-
mic cells because STAT5 activation leads to increased
expression of genes driving cell cycle progression and
promoting survival [45,46], but it still remains unclear
whether STAT5 is involved in regulating telomerase,
which plays critical role in tumor cell growth and
proliferation.
We present here several lines of evidence for a role of
S T A T 5i nt e l o m e r a s er e g u l a t i o ni nB C R - A B Lp o s i t i v e
K562 cells. We have shown that Gleevec treatment
reduced STAT5 phosphorylation, which coincides with
ad e c r e a s ei nhTERT mRNA expression. We also found
that STAT5 inhibitor selectively suppressed hTERT
mRNA expression and TA in BCR-ABL positive K562
cells. It has been known that STAT5 comprises of two
highly homologous genes encoding STAT5a and
STAT5b [47]. Although these two STAT proteins share
considerable functional overlap, gene-disruption experi-
ments have revealed that STAT5a and STAT5b are
functionally not redundant [48,49]. Previous studies
demonstrated that STAT5a mediates prolactin signaling
along with mammary gland development [48,50],
whereas knockdown of STAT5b abrogates sexually
dimorphic liver gene regulation and is associated with
loss of male characteristic body growth rates [51]. In
this study, we demonstrated that STAT5a, but not
STAT5b, expression and phosphorylation correlated
with hTERT gene expression and TA. More importantly,
knockdown of STAT5a as well as Gleevec treatment
severely reduced hTERT gene expression and TA in
BCR-ABL positive K562 cells but not in BCR-ABL nega-
tive HL60 cells. These results strongly support the
notion that constitutive activation of STAT5a is likely to
make a significant contribution to the telomerase regu-
lation in BCR-ABL positive CML cells, suggesting that
STAT5a could be an attractive target for the treatment
of CML, especially in cases of multiple inhibitor-resis-
tant CML. Our findings are in accordance with recent
reports which demonstrated that STAT5 accounts for
t h er e s i s t a n c ea g a i n s tG l e e v e ca n di n h i b i t i o no fS T A T 5
can effectively decrease survival of CML cells resistant
to tyrosine kinase inhibitors [52,53].
It is known that protein phosphorylation is an impor-
tant post-translational regulation controlling protein
structure and function [54]. Some reports indicated that
PKC can stimulate TA through phosphorylation of
hTERT, while TA was markedly inhibited in the pre-
sence of protein phosphatase 2A (PP2A) [55]. These
findings suggest that PKC and PP2A are involved in
reciprocally controlling TA through phosphorylation
and dephosphorylation. In addition to PKC, AKT was
also found to phosphorylate the serine residue at posi-
tion 824 of hTERT and stimulate TA [20]. In our study,
immunoprecipitation assay demonstrated that the
hTERT tyrosine phosphorylation level was higher in
K562 cells compared to HL60 cells and Gleevec treat-
ment could effectively abrogate hTERT tyrosine phos-
p h o r y l a t i o ni nK 5 6 2c e l l sa sw e l la sT Ai n h i b i t i o n ,
suggesting that BCR-ABL could also phosphorylate
hTERT and this phosphorylation may be important for
TA maintenance and regulation. However, further inves-
tigations are necessary to determine which tyrosine
could be the substrate of BCR-ABL. Previous results
demonstrated that c-ABL, a non-receptor tyrosine
kinase, can directly interact with hTERT and inhibit TA
following phosphorylation of hTERT [56]. This suggests
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function and as such we determined whether c-ABL
could affect TA and hTERT protein level in c-ABL
-/-
mouse embryonic fibroblasts (MEFs). We found that
there was no significant effect on TA and hTERT
expression by the c-ABL deficiency (Additional file 1:
Figure S13).
Previously, Liu and colleagues reported that phosphor-
ylation of hTERT may be an important mechanism to
regulate hTERT subcellular translocation from the cyto-
sol to the nucleus [37]. Presumably, the translocation of
hTERT from a non-functional cytosolic location to a
physiologically relevant nuclear location may play an
important role in regulating TA in cells. As we revealed
here that hTERT could be phosphorylated by BCR-ABL,
we next questioned whether BCR-ABL could also gov-
ern hTERT translocation in different cellular compart-
ments. Our confocal images have shown that hTERT in
K562 BCR-ABL positive cells were localized and con-
centrated in nucleoli at normal conditions. Under Glee-
vec treatment, most of the hTERT dissociated from
nucleoli into the nucleoplasm. In contrast, this phenom-
enon was not observed in HL60 and Jurkat, BCR-ABL
deficient cells. This implies that Gleevec treatment
could possibly inhibit phosphorylation of hTERT, induce
hTERT translocation and thereby decrease telomerase
enzyme assembly and subsequent activity.
We suppose that hTERT could be phosphorylated by
BCR-ABL directly since hTERT tyrosine phosphoryla-
tion level was found elevated in K562 cells by immuno-
precipitation assay (Figure 4b). In addition, the
expression level of hTERT was similar in both cells.
This result suggests that hTERT could be phosphory-
lated by BCR-ABL. Moreover, as shown in Figure 4c,
Gleevec treatment resulted in near-elimination of
hTERT phosphorylation at tyrosine residues compared
to control. We also demonstrated that the decrease in
tyrosine phosphorylation of hTERT was not due to
reduced hTERT expression level (Figure 4c). However,
our immunoprecipitation results showed that neither c-
ABL nor BCR-ABL interacts with hTERT directly,
which contradicts to a previous study that reported the
association of c-ABL with hTERT [56]. This may due to
the low affinity binding of BCR-ABL to hTERT or their
transient interaction. A previous study has shown that
BCR-ABL is a large protein mainly found in the cyto-
plasm, whereas hTERT is mostly localized in the
nucleus, excluding the possibility of a direct association
between the two proteins [25]. This also implies that
there may be another indirect regulation of BCR-ABL
on hTERT, which may require alternative pathways or
through some other intermediate proteins.
Taken together, we show here that BCR-ABL inhibi-
tion by Gleevec treatment has a significant impact on
telomerase regulation based on our findings (Figure 6).
Our study reveals a link between transcription factor
STAT5a and hTERT gene expression in BCR-ABL posi-
tive CML cell lines. Inhibition of BCR-ABL, and thus
STAT5a, by Gleevec leads to reduced TA and hTERT
mRNA expression as well as downregulation of hTERT
phosphorylation at tyrosine residues at the post-transla-
tional level. In addition to that, we also found that BCR-
ABL might regulate TA through the Wnt signaling
pathway (unpublished data). These findings support the
notion that telomerase expression and activity could be
regulated at multiple levels by the same protein. Shut-
tling of telomerase in and out of nucleoli induced by
Gleevec treatment provides a new insight on BCR-ABL
regulated TA.
The introduction of Gleevec has revolutionized the
treatment of CML. Despite significant hematologic and
cytogenetic responses, there has been concern over the
emergence of resistance to Gleevec, which is mostly due
to point mutations in the BCR-ABL kinase domain. One
such mutation, T315I, renders CML cells completely
resistant not only to Gleevec but also to second genera-
tion BCR-ABL inhibitors nilotinib and dasatinib [57].
This has spurred the interest in developing novel tyro-
sine kinase inhibitors or treatment strategies to over-
come the mechanisms of resistance that have led to
treatment failures. Our findings showed that STAT5,
more particularly, STAT5a, plays a critical role in TA
regulation, suggesting that inhibition of STAT5a in
combination with BCR-ABL may provide an alternative
approach for treatment of leukaemia, especially in
patients who are resistant to tyrosine inhibitors.
Figure 6 Hypothetical model of BCR-ABL tyrosine kinase
regulation on TA in K562 cells.
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STAT5 has been implicated in growth suppression in
CML cells but not in normal cells [58,59]. Such a com-
bination may allow less dose of each drug, and therefore
decrease side effects. More importantly, this strategy can
decrease the emergence of drug-resistant cells.
Conclusions
Our data suggest that BCR-ABL can regulate TA at
multiple levels, including transcription, post-transla-
tional level, and proper localization. Therefore, suppres-
sion of cell growth and induction of apoptosis by
Gleevec treatment may be partially due to TA inhibi-
tion. More importantly, we have identified STAT5a as
critical mediator of the hTERT gene expression in BCR-
ABL positive CML cells, suggesting that targeting
STAT5a may be a promising therapeutic strategy for
BCR-ABL positive CML patients, especially for resistant
cases due to mutants of BCR-ABL.
Additional material
Additional file 1: Supplemental data. Regulation of hTERT by BCR-ABL
at multiple levels in K562 cells.
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